Abeona Therapeutics Financials - Benzinga

Abeona Therapeutics Inc

ABEONASDAQ

Trade with Public

Trade with Public

$5.81

0.223.94%

Ult. Agg.: Sep 18, 9:30 AM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Abeona Therapeutics Financials

Abeona Therapeutics (ABEO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.23) by 52.17 percent. This is a 5.41 percent increase over losses of $(0.37) per share

Benzinga Newsdesk

PRO
Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 25 percent decrease over losses of $(0.24) per share from

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 4.49 percent. This is a 142.86 percent decrease over losses of $(0.14) per share

Benzinga Newsdesk

Earnings Scheduled For March 17, 2026

Benzinga Insights

PRO
Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.29) by 65.52 percent. This is a 84.13 percent increase over losses of $(0.63) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved